First-Ever Cannabis Product Approved for Import Into Mexico, RSHO-X™, Made in San Diego on Display as Elizalde Advocates for Medical Cannabis in Mexico
San Diego, CA – August 2, 2016 – Medical Marijuana, Inc. (OTC: MJNA) announced today that medical cannabis activist Raul Elizalde of Mexico will join Company representatives at the Southern California Cannabis Conference and Expo (SocalCCExpo) at the San Diego Convention Center to discuss his fight to unify the voices of families and patients in need of medical cannabis in Mexico.
Raul Elizalde and his family were the first in Mexico to sue the federal government and win the right to import cannabidiol (CBD) hemp oil to treat their daughter Grace’s severe form of epilepsy known as Lennox-Gastaux Syndrome. Raul’s victory for his daughter created the legal precedent for other families in Mexico to gain access to CBD, including the Maldonados, who were granted the first-ever federal import permit from the Mexican government for Medical Marijuana, Inc.’s Real Scientific Hemp Oil-X™ (RSHO-X™) for their 11-year-old daughter Alina.
RSHO-X™, made by San Diego-based Medical Marijuana, Inc., will be on display at the sponsored Pavilion #509 for Medical Marijuana, Inc. subsidiary company HempMeds®, where HempMeds® will be launching its new wholesale business and interviewing job applicants that have emailed resumes to firstname.lastname@example.org.
“Elizalde speaks from his heart, and we’re thrilled that he’ll be at the Expo in person to discuss his passionate fight for providing the best quality of life for his daughter, Grace, and others throughout Mexico,” said Dr. Stuart Titus, the CEO of Medical Marijuana, Inc. “Day-by-day we are working to change the world’s perception of medical marijuana, and it’s the tireless efforts of advocates like Elizalde, who are helping us make major strides toward this effort. One person can truly make a difference.”
Medical Marijuana, Inc.’s HempMeds® Mexico partners with Elizalde’s not-for-profit Por Grace Foundation, which he established to ensure families receive the right to health care and access to CBD hemp oil and to advocate for medical marijuana legalization in Mexico. The partners’ combined efforts have led to major changes in Mexico’s marijuana policy, as Mexico President Pena Nieto announced on April 21, 2016, his intent to move the country away from marijuana prohibition and towards prevention and regulation, including medicinal use.
Elizalde will also speak as part of the Expo’s “Children and Cannabis, Safety & Health” panel, which will be hosted by Medical Marijuana, Inc.’s PR firm CMW Media on Aug. 7 at 12 p.m. Joining Elizalde on the panel will be three-year-old San Diego girl Sadie Higuera and her father Brian Higuera, who will share Sadie’s miraculous story with medical cannabis; and Dallas mom and RSHO™ advocate Penny Howard will also speak with her 8-year-old daughter Lily about how sharing her late daughter Harper’s story to Facebook helped a family in Brazil. Through the Hope4Harper non-profit, Penny raises awareness for CDKL5, directly leading to a series of challenges to marijuana policies in Brazil.
For more information on HempMeds® and their all-natural hemp oil products, visit: www.hempmeds.com. For more information on the SocalCCExpo, visit: https://socalccexpo.com or the HempMeds® SocalCCExpo site.
HempMeds® offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC Pink: MJNA) and the Company’s exclusive master distributor and contracted marketing company.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.